Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies (Q38378992)

2 September 2017

1 reference

title

Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies (English)

1 reference

2 September 2017

0 references

1

1 reference

2 September 2017

Matthew Bates

6

0 references

Rosella Centis

Rosella Centis

3

0 references

Markus Maeurer

Markus Maeurer

Giovanni Battista Migliori

12

0 references

Giovanni Battista Migliori

13

0 references

Peter Mwaba

5

Peter Mwaba

1 reference

2 September 2017

11

Michael Hoelscher

1 reference

2 September 2017

7

Nathan Kapata

1 reference

2 September 2017

10

Sayoki Mfinanga

1 reference

2 September 2017

Jeremiah Chakaya

2

1 reference

2 September 2017

Lia D'Ambrosio

4

1 reference

2 September 2017

Thomas Nyirenda

8

1 reference

2 September 2017

Duncan Chanda

9

1 reference

2 September 2017

9 March 2015

1 reference

The Lancet. Respiratory medicine

2 September 2017

1 reference

2 September 2017

3

1 reference

2 September 2017

3

1 reference

2 September 2017

220-234

1 reference

Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis

2 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Pulmonary resection for patients with multidrug-resistant tuberculosis: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Surgical treatment of drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Rediscovering high technology from the past: thoracic surgery is back on track for multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Initiating antiretrovirals during tuberculosis treatment: a drug safety review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Timing of initiation of antiretroviral drugs during tuberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Integration of antiretroviral therapy with tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Treatment of latent tuberculosis infection.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Delamanid for multidrug-resistant pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Multidrug-resistant tuberculosis and culture conversion with bedaquiline.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

A four-month gatifloxacin-containing regimen for treating tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Medical inpatient mortality at Groote Schuur Hospital, Cape Town, South Africa, 2002-2009.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Prevalence, hemodynamics, and cytokine profile of effusive-constrictive pericarditis in patients with tuberculous pericardial effusion

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Adjuvant corticosteroids for tuberculous pericarditis: promising, but not proven

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Mycobacterium w Immunotherapy for Treating Pulmonary Tuberculosis - a Systematic Review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Advances in the development of new tuberculosis drugs and treatment regimens

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Nonsteroidal Antiinflammatory Drugs for Adjunctive Tuberculosis Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Adjunct immunotherapies for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Effect of ivermectin on the cellular and humoral immune responses of rabbits.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Dynamic compaction of human mesenchymal stem/precursor cells into spheres self-activates caspase-dependent IL1 signaling to enhance secretion of modulators of inflammation and immunity (PGE2, TSG6, and STC1).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Are clinical trials with mesenchymal stem/progenitor cells too far ahead of the science? Lessons from experimental hematology

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Scaling up interventions to achieve global tuberculosis control: progress and new developments

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

Drug-resistant tuberculosis: time for visionary political leadership

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900063-6

7 January 2021

10.1016/S2213-2600(15)00063-6

Identifiers

DOI

1 reference

2 September 2017

1 reference